“rapidd” Accelerating Early Stage Development, Minimising Cash Burn

October 14, 2009

Almac report strong demand in rapidd™ – an early stage development package taking lead drug development candidates to Phase I regulatory submission in under 12 months.  Setting a new standard for early stage development packages, rapidd™ was showcased for the first time at CPhI 2009 in Madrid. rapidd™ is being offered by Almac in conjunction with a number of market leading contract research organizations (CROs) – including Covance.

A complete set of solutions, rapidd™ – accelerated process integrated drug development – creates opportunities for added value in pre-clinical development, while offering significant savings.These include reduced cash burn, earlier milestones attainment and competitive advantage from an accelerated drug programme.   rapidd™ clients will release management time for added value creation, with time saving-to-market speeding investment returns.

Rapidd™ is a flexible, integrated package offered on a single-contract and managed by a dedicated team under a single contact/project manager. Dramatic savings against conventional lead times come from programme optimisation and avoidance of tech transfer time and other multiple partner issues.

“Rapidd™ rewrites the standard for early stage development packages. The shorter timelines and reduced cash consumption have clear benefits for new product time and cost-to market”,

commented Almac Sciences’ President and Managing Director Director Stephen Barr.

“Almac’s range of integrated, single-site services and capabilities also brings potential for added value in pre-clinical development”,

he added.

Peter Sausen, Global Vice President of Integrated Drug Development at Covance, commented:

“In continually exploring ways to integrate and streamline drug development processes for global clients, we are delighted to be working with Almac on their rapidd™ programme.”

RapiddTM provides all aspects of early stage development including small molecule or peptide API manufacture, formulation development, non-clinical safety assessment, regulatory support and clinical trial supplies.

The rapidd™ service package enables flexible approaches to client requirements and integrated drug development to CTA, FIM or POC.


– ENDS –

For further information contact:  

Denis Geffroy

VP Business Development – Almac Sciences

Tel: +44 (0)28 3833 2200

Fax: +44 (0)28 3833 2299

[email protected]

About Almac Group:

Almac is a financially stable, privately owned organisation with over 30 years experience, it provides integrated development solutions to over 600 customers worldwide including all the world leaders in the pharmaceutical and biotechnology sectors. Their services include R&D, translational genomic services; API manufacture; formulation development; clinical trial supply and technology (IVRS/IWRS/ePRO) and commercial-scale manufacture.

The company has over 2,500 employees and is headquartered in Craigavon, Northern Ireland, where it was awarded “Business of the Year 2009”.  US operations are based in Pennsylvania, North Carolina and California.  Construction of the company’s new $112m North American Headquarters in PA started in July 2008 and will be completed in 2010.

For more information about the Almac Group, please visit almacgroup.com or e-mail [email protected].


Back to news